Graves'病和Hashimot病患者可溶性细胞间粘附分子-1的研究

The study of sICAM-1 in patients with Graves'disease or Hashimoto disease

目的 :研究单纯甲状腺肿、Graves'病和Hashimot病患者血清sICAM -1的含量。方法 :用本室研制的sICAM -1RIA ,检测本市400例正常人以及1020例患有单纯性甲肿、Graves'病或者Hashimoto病患者血清sICAM -1含量 ,进行比较分析。结果 :正常人检测结果 (x±s)为 :168.43±36.23μg/L。单纯性甲肿组与正常组无显著性差别 (P>0.05) ,两种自身免疫性甲状腺疾病 (Graves'病和Hashimoto)均明显高于正常组和单纯性甲肿组(P<0.05)。3种治疗均可降低Graves'病患者sICAM -1含量 (P<0.05)。Graves'病停药复发组sICAM -1含量明显高于药物治疗后甲状腺功能恢复正常的Graves'病组(P<0.05)。结论 :sICAM -1RIA可用于临床检测自身免疫性甲状腺疾病 ;血清sICAM -1含量可作为自身免疫性甲状腺疾病诊断的一个参考指标 ,并在临床评价Graves'病的疗效、停药和复发等方面具有重要意义。

Objective: To study the serum sICAM-1 level in patients with single goitre, Graves'and Hashimoto disease. Methods: With 125I-sICAM-1 RIA, the serum sICAM-1 levels of 400 health individuals as normal group and 1020 patients with single goitre, Graves'or Hashimoto disease were examined and analysed. Results: The serum sICAM-1 level(x±s) in normal group were 168.43±36.23μg/L. There was no significant difference between normal group and single goitre group, whereas the serum sICAM-1 levels in autoimmune thyroid diseases (Graves'or Hashimoto) were higher than those in normal group or single goitre group(P<0.05, respectively).After Graves' patients received one of three medical treatments, their serum sICAM-1 level can be decreased (P<0.05).After the Graves'patients were treated and their thyroid function were normal, their serum sICAM-1 levels were lower than those in relapse Graves'patients (P<0.05).Conclusion: sICAM-1 RIA can be used to examine autoimmune thyroid diseases. sICAM-1 can be used a parameter in diagnosing autoimmune thyroid diseases and in evaluating effects of therapy, stopping medicine or the relapse of Graves'disease.